ArticleThe European respiratory journal2016
First case of extensively drug-resistant tuberculosis treated with both delamanid and bedaquiline.
Article in The European respiratory journal, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline.American journal of respiratory and critical care medicine · 2019Guideline
- Combined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review.International journal of molecular sciences · 2017Pooled it
- Safety, Tolerability, and Pharmacokinetics of Telacebec (Q203), a New Antituberculosis Agent, in Healthy Subjects.Antimicrobial agents and chemotherapy · 2022Trial
- Global trajectory and spatiotemporal epidemiological landscape of multidrug-resistant tuberculosis of spanning 46 years (1990-2035): implications for achieving global end TB goals.Frontiers in public health · 2025Article
- Novel Treatment for Pre-XDR Tuberculosis Linked to a Lethal Case of Acute Myocarditis.Diagnostics (Basel, Switzerland) · 2024Article
- A Narrative Review of Bedaquiline and Delamanid: New Arsenals Against Multidrug-Resistant and Extensively Drug-Resistant Mycobacterium tuberculosis.Journal of clinical laboratory analysis · 2024Review
- Impact of Prior Tuberculosis Treatment With New/Companion Drugs on Clinical Outcomes in Patients Receiving Concomitant Bedaquiline and Delamanid for Multidrug- and Rifampicin-Resistant Tuberculosis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Article
- Anti-tubercular profile of new selenium-menadione conjugates against Mycobacterium tuberculosis H37Rv (ATCC 27294) strain and multidrug-resistant clinical isolates.European journal of medicinal chemistry · 2021Article
- Promising Lead Compounds in the Development of Potential Clinical Drug Candidate for Drug-Resistant Tuberculosis.Molecules (Basel, Switzerland) · 2020Review
- Recent evidence on delamanid use for rifampicin-resistant tuberculosis.Journal of thoracic disease · 2019Article
- Bedaquiline and delamanid in the treatment of multidrug-resistant tuberculosis: Promising but challenging.Drug development research · 2019Review
- Telemedicine in Resource-Limited Settings to Optimize Care for Multidrug-Resistant Tuberculosis.Frontiers in public health · 2019Article
- Tuberculosis Status and Coinfection of Pulmonary Fungal Infections in Patients Referred to Reference Laboratory of Health Centers Ghaemshahr City during 2007-2017.Ethiopian journal of health sciences · 2018Article
- Nanotechnology in Tuberculosis: State of the Art and the Challenges Ahead.Pharmaceutical research · 2018Review
- Tuberculosis elimination: where are we now?European respiratory review : an official journal of the European Respiratory Society · 2018Review
- Delamanid for rifampicin-resistant tuberculosis: a retrospective study from South Africa.The European respiratory journal · 2018Article
- New and repurposed drugs to treat multidrug- and extensively drug-resistant tuberculosis.Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia · 2018Review
- Bedaquiline and Delamanid Combination Treatment of 5 Patients with Pulmonary Extensively Drug-Resistant Tuberculosis.Emerging infectious diseases · 2017Article
- Delamanid and bedaquiline to treat multidrug-resistant and extensively drug-resistant tuberculosis in children: a systematic review.Journal of thoracic disease · 2017Review
- Clinical Implications of New Drugs and Regimens for the Treatment of Drug-resistant Tuberculosis.Chonnam medical journal · 2017Review
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.